title: [Pancreatic cancer. The relative importance of neoadjuvant therapy].
abstract: Neoadjuvant radiochemotherapy in patients suffering from pancreatic cancer is presently not well established. Neoadjuvant radiochemotherapy is recommended to be applied in 5-8 weeks. The full dose of radiotherapy is between 50 and 54 Gy with 5FU used as radiosensitator. In patients with resectable pancreatic cancer, particularly in UICC-stage II neoadjuvant radiochemotherapy, this results in an improvement in survival: the median survival is between 15 and 30 months. In about 15% of the patients with resectable pancreatic cancer (UICC I-III), neoadjuvant radiochemotherapy results in downstaging. In combination with a R0-resection,neoadjuvant radiochemotherapy effects a reduction of local recurrence. Results from controlled clinical trials are necessary to objectify the benefits of neoadjuvant radiochemotherapy.
authors.affiliation: Donau- und Illertalklinik GmbH,Zentrum für Viszeralchirurgie, Illertissen. hans.beger@medizin.uni-ulm.de
authors.forename: H G
authors.initials: HG
authors.lastname: Beger
authors.forename: B
authors.initials: B
authors.lastname: Poch
authors.forename: M
authors.initials: M
authors.lastname: Schwarz
authors.forename: F
authors.initials: F
authors.lastname: Gansauge
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D018849:Controlled Clinical Trials as Topic; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011183:Postoperative Complications / Q000517:prevention & control; D011446:Prospective Studies; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D013311:Streptozocin / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D011838:Radiation-Sensitizing Agents; D013311:Streptozocin; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil